Compare
Bristol Myers Squibb vs Lilly (Eli) (BMY vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Bristol Myers Squibb (BMY) returned +33.7% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are +15.2% and +26.0%.
Lilly (Eli) is the larger company by market value, about 10.0 times the size of Bristol Myers Squibb.
On trailing earnings, BMY trades at 13.8 times and LLY at 43.9 times.
Revenue grew +4.2% at BMY and +45.5% at LLY over the last year.
BMY yields 3.04%. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| BMY | LLY | |
|---|---|---|
| Price | $62.14 | $1,354.00 |
| 1-day | -1.57% | -0.79% |
| YTD | +15.20% | +25.99% |
| 1 year | +33.72% | +46.25% |
| 3 years | +21.18% | +144.20% |
| Market cap | $127.0B | $1.27T |
| P/E | 13.8 | 43.9 |
| P/S | 2.54 | 14.73 |
| P/B | 5.43 | 31.63 |
| Revenue growth | +4.20% | +45.50% |
| EPS growth | +52.40% | +50.70% |
| Gross margin % | 69.2 | 83.6 |
| Net margin % | 18.5 | 31.9 |
| ROE % | 39.5 | 68.5 |
| Debt / equity | 1.83 | 1.23 |
| FCF yield % | 7.3 | 2.4 |
| Dividend yield % | 3.04 | 0.49 |
| Beta | 0.25 | 0.29 |
| RSI (14) | 51.3 | 61.1 |
| Technical rating |